The Institute for Clinical and Economic Review (ICER) hosted a public meeting last week to discuss new treatments for migraines.
According to a Pink Sheet report, ICER discussed its work with Allergan to assess the value of Ubrelvy.
ICER President Steve Pearson also reiterated during a policy roundtable that “price is access,” according to the report.
To read the full report on The Pink Sheet, click here. (Paid subscription required)